Type II DNA topoisomerases catalyse DNA double-strand cleavage, passage and re-ligation to effect topological changes. There is considerable interest in elucidating topoisomerase II roles, particularly as these proteins are targets for anti-cancer drugs. Here we uncover a role for topoisomerase IIa in RNA polymerase I-directed ribosomal RNA gene transcription, which drives cell growth and proliferation and is upregulated in cancer cells. Our data suggest that topoisomerase IIa is a component of the initiation-competent RNA polymerase Ib complex and interacts directly with RNA polymerase I-associated transcription factor RRN3, which targets the polymerase to promoter-bound SL1 in pre-initiation complex formation. In cells, activation of rDNA transcription is reduced by inhibition or depletion of topoisomerase II, and this is accompanied by reduced transient double-strand DNA cleavage in the rDNA-promoter region and reduced pre-initiation complex formation. We propose that topoisomerase IIa functions in RNA polymerase I transcription to produce topological changes at the rDNA promoter that facilitate efficient de novo pre-initiation complex formation.
T opoisomerases cleave DNA to elicit topological changes, facilitating DNA-processing events in cells, including transcription [1] [2] [3] . The type II topoisomerases (Top2) relax supercoiled DNA by a double-strand DNA passage reaction. There is much interest in understanding the cellular roles of the Top2 enzymes, the mechanisms and sites of action and the processes involved in recruitment to these sites, particularly as these proteins are targets for clinically important anti-cancer drugs [4] [5] [6] . In transcription, Top2 activity has been implicated in resolving supercoiling associated with elongation by RNA polymerases [7] [8] [9] [10] [11] [12] . In RNA polymerase I (Pol I) transcription, in yeast, Top2 cleavage resolves the positive supercoiling ahead of the elongating polymerase, whereas Top1 resolves negative torsion behind the polymerase 7 and, in mammalian cells, Top1 has been shown to have an important role in Pol I transcription elongation [13] [14] [15] . Mammalian cells have two isoforms of Top2, a and b, with similar enzymatic activities and 68% overall sequence identity, but Top2a and b differ markedly in their C-terminal domains (CTDs), which appear to determine isoform-specific functions. Top2a, specifically, is essential for chromatid segregation and decatenation G2-checkpoint function 16, 17 , for instance, whereas, Top2b is involved in the repair of DNA crosslinks and the transcriptional induction of a subset of hormoneand developmentally regulated genes in Pol II transcription [18] [19] [20] [21] [22] . To our knowledge, a Top2a-specific role in transcription has not yet been described. Intriguingly, our proteomic analyses of Pol I complexes had revealed, previously, the specific co-purification of Top2a with the initiation-competent Pol Ib complex 23 . Pol I transcription produces the major ribosomal RNA (rRNA) constituents of the protein-synthesis machinery, driving cell growth and proliferation and, thereby, influencing cell fate 24, 25 . Upregulation of Pol I transcription is linked to the unrestrained growth and proliferation characteristic of cancer cells 26, 27 .
Here we present evidence for a role for Top2a in the early stages of the Pol I transcription cycle. We demonstrate that Top2a is a component of Pol Ib and can bind to the RRN3 component of Pol Ib, which bridges the interaction between Pol I and basal transcription factor SL1 at the rRNA gene promoter [28] [29] [30] . We found that drug-induced inhibition of Top2 activity did not prevent elongation of rRNA transcripts. Our data suggest a novel and specific role for Top2a activity in facilitating de novo preinitiation complex (PIC) formation in rRNA gene transcription. Top2 inhibitors produced a defect in activation of Pol I transcription, independently of the DNA-damage response pathways, suggesting that drugs designed to target Top2a in Pol I transcription could be useful non-genotoxic agents in the treatment of cancer.
Results

Active Top2a is a component of initiation-competent Pol Ib.
Pol I transcribes the rRNA gene repeats to produce the 47S prerRNA transcript that is processed into the 18S, 5.8S and 28S rRNAs 24, 25, 28, 31 . Two functionally distinct forms of Pol I complex can be extracted from the nucleus of human cells. The Pol Ia complex, the most abundant form of Pol I in nuclear extracts, is catalytically active but does not support promoter-specific initiation at an rRNA gene promoter. The Pol Ib complex accounts for B10% of Pol I activity and is competent for promoter-specific transcription initiation. Pol Ib is defined by the association of its Pol I core subunits with growth-regulated transcription initiation factor RRN3, which bridges the interaction between basal transcription factor SL1 and Pol I in formation of functional PICs at the rRNA gene promoter 24, 25, 28 . We have previously reported that Top2a co-fractionates with the Pol Ib promoter-specific transcription activity and is the major substrate for Pol Ib-associated CK2 in the Pol Ib complex 23 . We demonstrate that Pol Ib has an associated decatenation activity that is ATP-dependent and sensitive to non-hydrolysable ATP and Top2 inhibitor etoposide (Fig. 1a) . The decatenation activity and Top2a protein co-purify with the RRN3 component of Pol Ib (Supplementary Fig. S1a ). These data suggest that catalytically active Top2a is associated with the initiation-competent Pol Ib complex.
To substantiate an association of Top2a with Pol Ib in cells, we immunoprecipitated Pol I from nuclear extracts of HeLa cells transiently expressing Flag-tagged Pol I subunit CAST 32 , using Flag-specific antibodies, then immunoblotted the immunoprecipitates using antibodies specific for Top2a, RRN3 and Pol I subunits PAF53 and AC19. Top2a co-immunoprecipitated with Pol I in this experiment (Fig. 1b) . We also passed purified Pol Ib over a Top2a-antibody column and analysed proteins eluted from the column and proteins in the flow-through in immunoblot and promoter-specific transcription assays ( Supplementary Fig.  S1b-d) . Intriguingly, the majority of promoter-specific transcription activity was lost and most of the RRN3 protein was depleted from Pol Ib and retained on the Top2a-antibody column. Therefore, the specific Top2a antibody used disrupted Top2a and RRN3 interactions with Pol I. These data indicate that the majority of Pol Ib complexes purified from human cell nuclei include Top2a.
Top2a interacts directly with Pol Ib-specific component RRN3. We reasoned that a direct interaction between Top2a and Pol Ib might involve Pol Ib-specific component RRN3. Two polypeptides unique to Pol Ib bound to RRN3, the larger of which migrated similarly to full-length Top2a protein, in a Far-western analysis in which in vitro-translated 35 S-labelled hRRN3 was used to probe renatured Pol Ia or Pol Ib (Fig. 1c) . Moreover, there was a direct interaction between RRN3 and Top2a in a recombinant protein-binding assay, in which in vitro-translated RRN3 was incubated with in vitro-translated green fluorescent protein (GFP)-Top2a 33 on GFP-antibody beads (Fig. 1d) . To test the likely involvement of the isoform-specific CTD in the interaction of Top2a with RRN3, we used Top2a CTD-mutant proteins lacking the terminal 42 or 180 amino acids (st1 or st5, respectively). These were the shortest and longest of a series of CTD truncations shown to impair the ability of GFP-Top2a to rescue the conditional Top2a-mutant cell line HTETOP 33 from lethal Top2a depletion ( Supplementary Fig. S2 ). A C-terminaltruncated version of Top2a (st5, 180 amino-acid deletion) displayed significantly reduced interaction with RRN3 in the recombinant protein-binding assay (Fig. 1d) . To further assess Top2a-RRN3 interactions, nuclear extracts of HTETOP cells depleted of endogenous Top2a 33 and stably expressing GFPTop2a-wild type (WT) or -st1 (CTD 42 amino-acid deletion) were incubated with GFP-specific antibodies, and immunoprecipitates were immunoblotted using antibodies specific for Top2a, RRN3 and Pol I subunit PAF53. Endogenous RRN3 and Pol I subunit PAF53 co-immunoprecipitated with GFP-Top2a-WT (Fig. 1e ). There was a significant decrease (Bsixfold) in the amount of RRN3 that co-immunoprecipitated with the GFP-Top2a-st1 mutant, compared with GFP-Top2a-WT. There was also a decrease (Btwofold) in the amount of PAF53 co-immunoprecipitated; the smaller magnitude of this decrease might reflect interactions between Top2a and other components of the initiation-competent Pol Ib complex, such as CK2 23 .
Collectively, these data demonstrate that Top2a interacts directly with RRN3 and that residues 1491-1531 in the Top2a CTD are important for such interaction. Therefore, there is evidence, both in vitro and in cells, to support an interaction between Top2a and RRN3 as components of initiation-competent Pol Ib.
Top2a occupies the rDNA promoter in an SL1-dependent manner. The association of Top2a with initiation-competent Pol Ib predicts the presence of Top2a at the rDNA promoter. Top2a was detectable at the rDNA promoter by chromatin immunoprecipitation (ChIP) analysis in all cell types tested ( Fig. 1f and Supplementary Fig. S3) ; elsewhere, along the rDNA repeat, Top2a association varied according to cell type ( Supplementary  Fig. S3 ). Small interfering RNA-mediated depletion of the TAF I 41 subunit of SL1 in cells, which leads to the disappearance of SL1 and Pol I from the rDNA promoter and reduces Pol I transcription 34 , resulted in the loss of Top2a from the rDNA promoter ( Fig. 1f and g ). The data suggest that SL1, which binds to the rDNA promoter and recruits Pol Ib through RRN3, is required for the recruitment of Top2a to the rDNA promoter in cells and that the presence of Top2a at the rDNA promoter correlates with the presence of Pol Ib and Pol I transcription.
Top2a and RRN3 dissociate from Pol I following initiation. RRN3 dissociates from Pol I at an early step following initiation of transcription 35, 36 , and we have used a stalled Pol I transcription system 37 to assess whether Top2a and RRN3 both dissociate from Pol I following initiation of transcription. Pol I can be stalled at the position of the first T ( þ 31) on a 'T-less' template when the transcription reaction is carried out in the absence of UTP. Immobilization of the template allows the template-associated proteins to be separated from proteins that dissociate from the transcription complex after initiation of transcription. We demonstrate that Pol I subunit PAF53 was still associated with the DNA template following initiation of transcription, as expected for a stalled Pol I complex (Fig. 2a,  lane 1) , whereas RRN3 and Top2a were present in the reaction supernatant (Fig. 2a, lane 2) . Note that in control transcription reactions supplemented with all four NTPs, Pol I transcribes to the end of the template, whereupon it dissociates in the presence of excess competitor DNA (Fig. 2a, lane 3) and, consequently, Pol I and Pol I-associated factors were present in the reaction supernatant (Fig. 2a, lane 4) . Therefore, both Top2a and RRN3 dissociate from Pol I following initiation of transcription in vitro (Fig. 2b) , consistent with a tethering of Top2a to Pol I, at least in part, through RRN3. Should Top2a indeed dissociate from Pol I at initiation or during/immediately following promoter escape in cells, any role for Pol Ib-associated Top2a in Pol I transcription would be predicted to be at an early step in transcription. ARTICLE Effects of Top2 inhibition on Pol I transcription. To investigate a role for Top2a in early Pol I transcription events, we first tested the effects of inhibition of Top2 activity on Pol I transcription, using 3 H-uridine pulse-chase labelling of (pre-)rRNA in cells. We observed a negative effect on Pol I transcription of etoposide treatment of U2OS cells ( Supplementary Fig. S4 ). However, there is evidence to suggest that this was likely to be indirect and as a consequence of ataxia telangiectasia mutated (ATM)- 38 and p53-dependent DNA-damage signaling 39, 40 , activated by doublestrand DNA breaks arising from trapped Top2-DNA cleavage complexes 1 . Therefore, to assess whether inhibition of Top2 activity could induce any effects on Pol I transcription independent of DNA-damage signalling, we treated cells with alternative Top2 inhibitors and/or used cell lines that could not elicit a p53-dependent DNA-damage response. Crucially, treatment for up to 15 h of U2OS cells with merbarone (a Top2 catalytic inhibitor blocking DNA cleavage 41 ) and of p53-null H1299 cells with etoposide ( Fig. 3a-c ) produced no significant effects on Pol I transcription. As inhibition of Top2 activity for up to 15 h does not have a detectable direct effect on Pol I transcription in actively growing cell populations, this suggests that Top2 activity is not essential for transcription (re-)initiation or elongation of rRNA transcripts. Notably, Top2 inhibitor treatments for 24 and 48 h, of U2OS cells with merbarone or HCT116 (p53 null) cells with etoposide, resulted in significant decreases in Pol I transcription ( Fig. 3d-f ). These findings imply a potential role for Top2 in Pol I transcription, outside of (re-)initiation or elongation.
Top2a depletion negatively affects Pol Ib assembly/stability. To further explore the possibility of a role for Top2a in Pol I transcription, we analysed rRNA transcripts from HTETOP cells specifically depleted of the a-isoform of Top2 by treatment with tetracycline (Tet) for 48 h ( Fig. 4a and b ). In common with other cells depleted of Top2a protein or treated with Top2 catalytic inhibitors (reviewed in Nitiss 1 ), this impairs sister chromatid segregation causing aberrant anaphases and cytokinesis 16, 33 . After 48 h in Tet, the only mRNA transcripts to be dramatically depleted in HTETOP cells are those encoding Top2a itself 42 . Nevertheless, we detected an Btwofold reduction in Pol I synthesis of the 47S pre-rRNA transcript, with no effect on prerRNA processing (Fig. 4c) . Pol I was immunoprecipitated from the Top2a-depleted and control cells in equivalent amounts, as determined by the non-specific Pol I transcription activities of the immunoprecipitates (Fig. 4d ). Yet, there was significantly less promoter-specific transcription activity associated with Pol I immunoprecipitates from the Top2a-depleted cells (Fig. 4d ) and a reduced amount of RRN3 protein in these immunoprecipitates ( Fig. 4e) , compared with those of the control cells. These data suggest the presence of fewer initiation-competent Pol Ib complexes in Top2a-depleted cells. Such a decrease could account for the observed two-fold reduction in Pol I transcription in Top2a-depleted cells. Taken together, these results suggest that Top2a can influence the assembly and/or stability of initiation-competent Pol Ib at the rDNA promoter, and thereby PIC formation, in cells.
We reasoned that in a population of actively growing cells, at any one time, most of the active rDNA promoters are engaged in multiple-round transcription, with relatively few requiring de novo PIC formation and activation of transcription. De novo PIC formation is required at actively transcribing rDNA genes following DNA replication (on one set of duplicates). Lack of de novo PIC assembly would lead to a predicted B50% reduction in Pol I transcription with each cell cycle. Our data (Figs 3 and 4) suggest that in the absence of Top2a activity, there may be a gradual accumulation of rDNA promoters requiring de novo PIC formation to achieve transcription.
Top2a facilitates assembly of Pol I PICs. To investigate the involvement of Top2a in de novo PIC formation, we sought a system in which de novo functional PIC formation was required for Pol I transcription at the majority of rDNA promoters. Pol I transcription can be downregulated by serum starvation of cells and activated by serum refeeding 43, 44 . Starved U2OS cells exhibit decreased levels of Pol I transcription (Fig. 5a ), accompanied by reduction of SL1 and Pol I from the rDNA promoter (Fig. 5b ) and the disappearance of Top2a from the rDNA promoter (a) Using purified Pol Ib, SL1 and UBF, PICs were assembled at the rDNA promoter of an immobilized T-less template 'T28' (IT) 37 . Transcription reactions were performed in the presence of ATP, GTP and CTP ( À UTP, left panel) or all four NTPs ( þ UTP, right panel). Excess competitor DNA was added to transcription reactions to prevent re-association of factors with template. After completion of transcription, the reaction mix (Sup) was separated from the template (IT), which was then washed. Proteins bound to the template (lanes 1 and 3) and proteins released from the template into the reaction mix during transcription (Sup lanes 2 and 4) were subjected to SDS-PAGE and immunoblotting using antibodies to Top2a, RRN3 and PAF53. NATURE COMMUNICATIONS | DOI: 10.1038/ncomms2599 ARTICLE (as determined by ChIP) (Fig. 5b ) and the nucleolus (as determined by indirect immunofluorescence; Supplementary  Fig. S5 ). Activation of Pol I transcription occurs in starved H1299, U2OS and HTETOP cells following serum refeeding (Fig. 6a-c, respectively ). This activation correlates with an increase in SL1, UBF and Pol I promoter occupancies and the reappearance of Top2a at the rDNA promoter (Fig. 6d,e) , as well as increased Top2a expression and co-localisation of Top2a with Pol I in the nucleolus (Fig. 6f and Supplementary Fig. S5b ). Therefore, de novo functional PIC formation appears to be required for transcription at the majority of rDNA promoters reactivated in serum-refed cells. There are several hundred copies of the rRNA genes per cell, but only about half are active in cycling cells and sensitive to psoralen cross-linking, and these are in an open chromatin configuration. Despite the changes in Pol I transcription caused by starvation or growth-stimulation of cells, the proportion of rRNA genes in an open chromatin configuration remains constant 43, 45 . This suggests that the rRNA genes requiring de novo PIC formation for activation upon serum refeeding are likely to be from the pool of genes sensitive to psoralen cross-linking. We exploited this system to investigate the requirement for Top2a in de novo PIC formation in Pol I transcription.
There was a marked (Btwofold) reduction in activation of Pol I transcription in starved H1299 and U2OS cells treated with Top2 inhibitors etoposide and merbarone, respectively, then resupplied with serum, as determined by S1 nuclease protection of the first 40 nucleotides of the pre-rRNA (Fig. 6a,b) and by 3 H-uridine pulse-chase labelling ( Supplementary Fig. S6a,b) . Top2 inhibitor ICRF-193 similarly reduced activation of Pol I transcription in U2OS cells ( Supplementary Fig. S6d,e) . These data suggested a defect in the early stages of transcription. There was a corresponding reduced occupancy of SL1, UBF and Pol I, with little Top2a detectable, at the rDNA promoter in the H1299 cells (Fig. 6d) , suggesting that, inhibition of Top2 activity reduces the efficiency of PIC formation and, thereby, the efficiency of Pol I transcription activation. This defect in activation is likely to be independent of DNA-damage signalling through p53 and ATM as it occurred in p53-null cells (H1299) (Fig. 6a) and could not be rescued by incubation of cells with caffeine (an inhibitor of ATM/ ATR [ataxia telangiectasia and Rad3-related] signalling) (Fig. 6g) .
HTETOP cells depleted of Top2a protein, serum-starved, then resupplied with serum, also showed reduced activation of Pol I transcription and a corresponding reduced promoter occupancy of SL1, UBF and Pol I (Fig. 6c,e and Supplementary Fig. S6c ), complementing the results obtained by pharmacological inhibition of Top2.
Taken together, these results suggest that Top2 activity, specifically that of the a-isoform of Top2, facilitates the efficient de novo assembly of PICs in Pol I transcription.
Top2a induces DNA cleavage at the rDNA promoter in activation. We hypothesized that Top2a might influence de novo PIC formation in activation of Pol I transcription by producing topological changes at the rDNA promoter that would support efficient assembly of the PIC. We reasoned that double-strand DNA (dsDNA) cleavage would arise at the rDNA promoter from such Top2 activity, although short-lived, due to the re-ligation activity of Top2. Therefore, we analysed the rDNA-promoter region for DNA breaks. To this end, cells were fixed and permeabilized at different time points following serum refeeding, incubated with biotin-11-deoxyuridine triphosphate (dUTP) and deoxynucleotide transferase (TdT) to label DNA breaks, and then, DNA containing breaks was captured on streptavidin beads and analysed by qPCR, as described 19 . Strikingly, a significant increase in DNA cleavage at the rDNA promoter was detectable during the activation of Pol I transcription (Fig. 7a) . The time course demonstrates that the DNA cleavage is transient, peaking at the first detection of transcription activation and Top2a occupancy of the rDNA promoter. Importantly, no such DNA cleavage was detectable at the rDNA promoter in the Top2a-depleted and starved HTETOP cells upon serum refeeding (Fig. 7b) . Note that although enhanced DNA cleavage has been observed at other regions of the rDNA in some experiments upon serum refeeding and Pol I transcription activation, this was not a reproducible effect. In other control experiments, we did not observe any increase in DNA cleavage at the promoters of the glyceraldehyde-3-phosphate dehydrogenase and peptidylprolyl isomerase A genes upon serum refeeding ( Supplementary  Fig. S7 ).
Our data imply that, in activation of Pol I transcription, Top2a, specifically, induces the transient appearance of double-strand DNA breaks in the rDNA-promoter region, reflecting its dsDNA cleavage, strand passage and re-ligation activity. Taken together, the data suggest that Top2a activity at the rDNA promoter facilitates the efficient de novo assembly of functional PICs, which include SL1, UBF and Pol Ib (Fig. 7c) .
Discussion
This study identifies a novel function for a Top2 in facilitating de novo PIC formation and activation of Pol I transcription of the rRNA genes in human cells.
We present evidence of a role for the Top2a isoform in Pol I transcription. Our data suggest that active Top2a is a component of the initiation-competent Pol Ib complex, targeted to the rDNA promoter, at least in part, through the interaction of its isoformspecific C terminus with the RRN3 component of Pol Ib, which interacts with promoter-bound transcription factor SL1. Depletion of Top2a negatively affects the assembly and/or stability of initiation-competent Pol Ib and decreases Pol I transcription in cells, implying that Top2a can influence the assembly and/or stability of initiation-competent Pol Ib at the rDNA promoter and, thereby, PIC formation in cells. De novo PIC formation is an event expected to occur at the active rDNA gene promoters following DNA replication (on one set of the duplicates) during each cell cycle. De novo functional PIC formation is also required for activation of Pol I transcription at the majority of rDNA promoters upon refeeding of serum-starved cells, and we discovered that Top2a facilitates efficient activation of Pol I transcription from such promoters and that this is accompanied by Top2a-dependent DNA cleavage and accumulation of PIC components and Top2a at the rDNA-promoter region. Our data suggest a role for Top2a in de novo PIC formation, and we propose that Top2a facilitates efficient activation of Pol I transcription through its ability to cleave, passage and re-ligate dsDNA and, thereby, to alter the topology of the rDNA promoter, alleviating topological constraints to PIC assembly and stability (Fig. 7c) .
At the rDNA promoter, the local topology or higher-order structure 46, 47 of the DNA can influence transcription of the rRNA gene and can be affected by chromatin context, including binding of the architectural protein UBF, which bends and supercoils the promoter 48, 49 , and nucleosome positioning 50 . TBP-TAF complex SL1 directs Pol I PIC formation and stabilizes UBF at the rDNA promoter 51 . We envisage that, in activation of Pol I transcription, SL1 binds to the rDNA promoter, RRN3 binds to SL1 and Top2a is recruited through its interaction with RRN3, and then Top2a-mediated cleavage, passage and re-ligation of dsDNA at the rDNA promoter creates a topological state conducive to the efficient de novo assembly and stabilization of a functional PIC, including SL1, UBF and initiation-competent Pol Ib, so that transcription can now be initiated and re-initiated. Lack of Top2a catalytic activity during de novo PIC formation would reduce Pol I transcription activation by affecting the equilibrium of SL1 and UBF binding to the promoter and, thereby, the efficiency of Pol I recruitment. negative supercoils behind 7,12 could potentially be dissipated by the actions of the adjacent polymerases 52 , such that topoisomerase activity would not be required, except perhaps ahead of a stalled polymerase or in regions where the density of polymerases is sparse. A polymerase pioneering the first round of activated transcription, without the advantage of an adjacent polymerase to dissipate the supercoiling it generates as it transcribes the rDNA would require topoisomerase cleavage. In the absence of Top2a, the observed decrease in occupancy by PIC components of the rDNA promoter might be accounted for if pioneering polymerases were stalled, due to the topological constraints imposed by failure to resolve supercoiling at or before promoter escape, thereby preventing the productive interaction of incoming PIC components with the rDNA promoter. We considered the possibility that Top2a might affect serumactivated de novo PIC formation by influencing the assembly of nucleosome remodelling machineries for repositioning of nucleosomes through a mechanism similar to that proposed for DNA topoisomerase IIb (Top2b) in ligand (hormone)-stimulated activation of Pol II promoters 19 , which involves recruitment of DNA-damage response proteins. However, such a mode of action seems unlikely, as key components of the repair machineries (such as Ku70, Ku80 and DNA-PK) were not detectable by ChIP analysis at the activated rDNA promoters (our unpublished results), suggesting that, if Top2a affects nucleosome positioning in activation of Pol I transcription, then it achieves this through alternative means.
Our findings reveal a novel dimension to the efficacy of Top2 inhibitors used in cancer treatment [4] [5] [6] and, potentially, to the search for Top2a-specific anti-cancer agents 5, 53 . De novo PIC formation and activation of Pol I transcription occur during each cell cycle at newly replicated rRNA genes and might also be required for the upregulation of Pol I transcription linked to cancer 26, 27 . We have demonstrated that the Top2 inhibitor etoposide, an effective anti-cancer drug, can reduce de novo PIC assembly and activation of Pol I transcription, independently of the p53 status of cells and the ATM/ATR-dependent DNAdamage response pathways. This suggests that this Top2 inhibitor might function in part to restrict Pol I transcription by limiting de novo activation of rRNA genes, which, ultimately, could lead to the abrogation of Pol I transcription, even in p53-null cells. This would have devastating consequences for protein synthesis, constraining the runaway growth associated with cancers. Indeed, maintenance of elevated levels of Pol I activity in cancer cells appears critically important for the process of malignant transformation and cancer cell survival. For instance, CX-5461, a selective inhibitor of Pol I transcription, induced p53-dependent apoptotic cell death in the majority of Em-Myc lymphoma cells at concentrations that reduced Pol I transcription about 50% (ref. 54 ). Recent studies have illustrated the effectiveness of targeting Pol I transcription in anti-cancer therapy for haematological malignancies 54 and solid tumours 55 . Therefore, we speculate that inhibitors specifically designed to target Top2a in Pol I transcription (which may be less likely to cause secondary cancers than those targeting the b-isoform 53 ) could be effective non-genotoxic tools for use in the battle against cancer.
Methods
Cell-culture conditions and Top2 depletion or inhibition. U2OS cells in McCoy's 5A medium plus 10% FBS, H1299 cells (homozygous partial deletion of p53) in RPMI plus 10% FBS and HTETOP cells (derivative of human fibrosarcoma cell line HT1080) in DMEM high glucose (4.5 g l À 1 ) plus 10% FBS and other additives 33 were grown to B60-70% confluency, washed twice with Dulbecco's PBS and then serum-starved for 20 h in DMEM low glucose (1 g l À 1 ). For activation of Pol I transcription, serum-starved cells were incubated in DMEM low glucose (1 g l À 1 ) containing 20% FBS. For Top2 inhibition, Top2 poison etoposide (100 mM final concentration; Merck) or catalytic inhibitors ICRF-193 (50 mM) and merbarone (100 mM; Merck) were added (except Fig. 6g ). For Top2a depletion, HTETOP medium was supplemented with 1 mg ml À 1 Tet for 48 h.
Cell and in vitro expression of GFP-Top2a fusion proteins. HTETOP cells expressing GFP-Top2a were as described (Clone H 33 ). Stop codons were introduced into pGFP-Top2a 33 by Quickchange site-directed mutagenesis (Agilent Technologies; see Supplementary Fig. S2 ). pGFP-Top2a-WT (full-length human; 1,531 amino acids) or pGFP-Top2a-st1 (stop-codon mutant) plasmids 33 (NotIlinearized) were electroporated into HTETOP cells, puromycin-resistant colonies were selected and single GFP-positive colonies were expanded. In vitro transcription/translation experiments used pGFP-Top2a-WT and -st5.
Immunocytochemistry. Cells were fixed (10 min, 4% paraformaldehyde), permeabilized (10 min, 1% Triton X-100) and blocked (10 min, 1% donkey serum in PBS), and then incubated (1 h) with antibodies (Supplementary Table S1 ) in the blocking buffer, washed X3 for 10 min in PBS and incubated (1 h) with labelled secondary antibodies (Supplementary Table S1 ). After washes, cells were mounted with Vectashield containing 4 0 ,6-diamidino-2-phenylindole and visualized using confocal microscopy.
RNA labelling in cells and rRNA analysis. Labelling of RNA in cells (B70% confluent or B50% for starved/refed) involved 10 mCi 3 H-uridine for B0.2-0.4 Â 10 5 cells per well of a six-well plate. In pulse-chase labelling, cells were incubated for 2 h with 3 H-uridine, washed and incubated in unlabelled medium containing 0.5 mM uridine ( þ / À Top2 inhibitors). RNA was extracted (RNeasy Mini Kit (Qiagen)). An amount of 2 mg of 3 H-labelled total RNA was run on a 1% formaldehyde agarose gel at 130 V for 90 min in X1 MOPS, blotted onto Hybond-N membrane (Amersham), cross-linked (ultraviolet cross-linker; UVP), analysed by tritium imaging using Fuji Tritium image plate (or following PerkinElmer En3Hance spray, exposed to Kodak Biomax XAR film at À 80°C) and then quantified using Aida software. S1 nuclease protection analysis of pre-rRNA levels. Total RNA isolation from cells (B70% confluent or B50% for starved/refed) and S1 nuclease protection analysis were performed with a 5 0 end-labelled oligonucleotide probe complementary to the first 40 nucleotides of the 47S pre-rRNA transcript 44 .
In vitro transcription assays. Non-specific transcription assays were performed as described 28 . Run-off transcription reactions were performed essentially as described 37 , using immobilized rDNA fragments containing the human rRNA gene promoter, supplemented with purified SL1 and recombinant UBF 56 . Reactions were terminated by addition of RTL buffer and RNA transcripts (purified using RNeasy mini kits (Qiagen)) were electrophoresed on denaturing 4% acrylamide/ 8 M urea gels, visualized by phosphorimaging FLA-7000 (Fuji) and analysed with Aida software.
Decatenation assay. DNA topoisomerase II activity was assayed by analysing decatenation of kinetoplast DNA (TopoGen), according to the manufacturer's protocols. AMP-PNP was substituted for ATP (200 and 100 mM) or Top2 inhibitor etoposide (250 and 100 mM) was included in some reactions. DNA products were resolved on a 1% agarose gel in TBE buffer.
Immunoblotting and immunoprecipitation. Antibodies used for immunoblotting and immunoprecipitations (IPs) are listed (Supplementary Table S1 ). IP of nuclear extracts, prepared as described 57 , from U2OS and HTETOP cells (±1 mg ml À 1 Tet) transfected (FuGENE HD reagent; Roche) with Flag-CAST expression vector pcFCAST 32 used anti-Flag M2 magnetic beads (Sigma) (for Pol I IP) for 2 h at 4°C.
The beads were washed three times in TM10/0.15 M KCl (TM10 buffer: 50 mM Tris-HCl pH 7.9, 12.5 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 1 mM sodium metabisulphite and 1 mM dithiothreitol). Washed precipitates were analysed by immunoblotting. IP of nuclear extracts from HTETOP GFP-Top2a cells used anti-GFP-antibody magnetic beads (for Top2a IP).
Protein-protein interaction assays. Far-western analysis was performed as described 28 . Pol Ia and b fractions were subjected to SDS-PAGE and transferred to an Immobilon-P (Millipore) membrane. After renaturation, the membrane was probed with FLAG-purified, 35 S-methionine-labelled hRRN3 and human Top2a antibody.
Interactions of GFP-tagged Top2a-WT and Top2a-st5 with Flag-tagged human RRN3 were analysed using 35 S-labelled in vitro-translated proteins (TNT-coupled reticulocyte lysate; Promega) in in vitro binding assays. Proteins were immunoprecipitated from the labelling reactions using anti-GFP, anti-FLAG and anti-HA antibody magnetic beads. Human RRN3 was eluted from washed beads using Flag-peptides and incubated with GFP-Top2a-WT/-st5 on beads. After binding (75 mM KCl in TM10 buffer with 0.015% NP40 and 1 mg ml À 1 BSA) for 30 min on ice, beads were washed (0.1 M KCl in TM10) and bound proteins were analysed by SDS-PAGE and autoradiography.
ChIP assay. Cells were subjected to cross-linking (1% formaldehyde, room temperature, 10 min; terminated by addition of glycine to a final concentration of 0.125 M for 5 min) and then chromatin was isolated as described 58 and sheered to B300 bp of average-size fragments (Bioruptor; Diagenode). A single ChIP used chromatin from 2.5 Â 10 5 or 1 Â 10 6 cells and antibodies as in Supplementary  Table S2 , incubated overnight at 4°C, and then for 2 h with Protein A/G beads (Invitrogen) at room temperature. Beads were washed five times in 450 ml volume of RIPA ChIP buffer 59 and twice with 200 ml TE buffer with aid of the Precipitor (Abnova). DNA on washed beads 59 was eluted, and cross-link reversal was performed in one stage as described 60 . DNA was purified (IPure kit; Diagenode with Precipitor; Abnova) and analysed by qPCR (QuantiFast Multiplex PCR Mix; Qiagen) in triplicates using primer combinations and probes covering regions of rDNA repeat (Supplementary Table S3 ) on Light Cycler 480-II (Roche). Results were expressed as percentage of input chromatin and normalized to control IgG levels. Bar graphs show the average from three independent experiments (n ¼ 3); s.d. and statistical significance (probability values: ***Po0.001; **Po0.01; and *Po0.05, for drug-treated versus control cells) have been calculated using one-and two-way analysis of variance on R software (open-source statistical computing and graphics software).
DNA double-strand break detection assay. Cells were fixed, permeabilized in situ and DNA breaks were labelled with biotin-11-dUTP and terminal TdT as described 19 . In brief, cells (15 cm dish per single experimental point) were washed with 37°C PBS and fixed for 20 min with Streck Fixative (0.15 M 2-bromo-2-nitropropane-1,3-diol, 0.1 M diazolidinyl urea, 0.04 M zinc sulphate heptahydrate, 0.01 M sodium citrate dihydrate and 50 mM EDTA) at room temperature and permeabilized by further incubation for 15 min at room temperature in PM buffer (0.1 M Tris-HCl, pH 7.5, 50 mM EDTA and 1% Triton X-100). Cells were washed six times with 10 ml of water before one wash with 3 ml of X1 TdT buffer containing 0.005% Triton X-100. Cells were subsequently incubated in 4 ml reaction buffer (X1 TdT buffer, 0.005% Triton X-100, 45 mM biotin-11-dUTP (Fermentas) and 250 U ml À 1 terminal deoxynucleotidetransferase (Promega)) for 90 min at 37°C on rotating platform. Cells were washed twice with 10 ml ice-cold TBS (50 mM Tris-HCl pH 7.5, 150 mM NaCl) and then carefully collected with a large cell scraper, pelleted by centrifugation and lysed in 200 ml lysis buffer (50 mM Tris-HCl pH 8.0, 10 mM EDTA and 2% SDS) for 15 min at 37°C. Chromatin was sheared using the Bioruptor (Diagenode) to 500 bp of average-size fragments, and diluted and biotinylated DNA fragments were captured with 50 ml of Streptavidin M280 magnetic beads (Invitrogen) for 2 h at room temperature. Beads were washed five times in 450 ml of RIPA ChIP buffer 59 and twice in 200 ml TE buffer with the aid of a Precipitor (Abnova). DNA elution was performed as described 60 . Purified DNA was analysed by qPCR using QuantiFast Multiplex PCR Mix (Qiagen) and the rDNA promoter-specific combination of primers and probe (see Supplementary Table S3 ) on Light Cycler 480-II (Roche). For the glyceraldehyde-3-phosphate dehydrogenase promoter control, we used the following forward and reverse primers: 5 0 -CAACGGATTTGGTCGTATTGG-3 0 and 5 0 -TGATGGCAAC AATATCCACTTTACC-3 0 with the probe 5 0 -TCACCAGGGCTGCTT-3 0 (Applied Biosystems). For the peptidylprolyl isomerase A gene promoter, the primers were as follows: 5 0 -CAAATGGTTCCCAGTTTTTCATC-3 0 and 5 0 -TTGCCAAACACC ACATGCTT-3 0 with the probe 5 0 -CACTGCCAAGACTG-3 0 (Applied Biosystems). PCR parameters were set as recommended by PCR Mix manufacturer (Qiagen). All PCR reactions were performed in triplicate and averages; s.d. and statistical significance (***Po0.001; **Po0.01; *Po0.05; by analysis of variance) were derived from three independent experiments (n ¼ 3). Results were expressed as percentage of input chromatin and normalized to control reactions where no biotin-11-dUTP was added at the labelling stage. 
